Concord Biotech Limited CC-Feb26.pdf
12 Feb 2026
-
So first question is on that you mentioned increased engagement on second source supply post clarity on U.S. tariffs. So, are these discussions largely with the existing customers or new innovator or generic players? And what is the kind o f conversion timeline that one should expect?
Read in transcript -
Understood. So how should we see the Q4, the exit run rate or as we enter FY '27, especially in the APIs? And second how should we see the formulation segment over the next 2 to 3 years?
Read in transcript